Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Gα/Gβγ protein complex

Grégoire P. Prévost; Marie O. Lonchampt; Susan Holbeck; Samir Attoub; Daniel Zaharevitz; Mike Alley; John Wright; Marie C. Brezak; Hélène Coulomb; Ann Savola; Marion Huchet; Sophie Chaumeron; Quang Dé Nguyen; Patricia Forgez; Erik Bruyneel; Mark Bracke; Eric Ferrandis; Pierre Roubert; Daniéle Demarquay; Christian Gespach; Philip G. Kasprzyk

doi:10.1158/0008-5472.CAN-05-4205

Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Gα/Gβγ protein complex

Grégoire P. Prévost, Marie O. Lonchampt, Susan Holbeck, Samir Attoub, Daniel Zaharevitz, Mike Alley, John Wright, Marie C. Brezak, Hélène Coulomb, Ann Savola, Marion Huchet, Sophie Chaumeron, Quang Dé Nguyen, Patricia Forgez, Erik Bruyneel, Mark Bracke, Eric Ferrandis, Pierre Roubert, Daniéle Demarquay, Christian GespachPhilip G. Kasprzyk

Research output: Contribution to journal › Article › peer-review

57 Citations (Scopus)

Abstract

A large number of hormones and local agonists activating guanine-binding protein-coupled receptors (GPCR) play a major role in cancer progression. Here, we characterize the new imidazo-pyrazine derivative BIM-46174, which acts as a selective inhibitor of heterotrimeric G-protein complex. BIM-46174 prevents the heterotrimeric G-protein signaling linked to several GPCRs mediating (a) cyclic AMP generation (Gαs), (b) calcium release (Gαq), and (c) cancer cell invasion by Wnt-2 frizzled receptors and high-affinity neurotensin receptors (Gαo/i and Gαq). BIM-46174 inhibits the growth of a large panel of human cancer cell lines, including anticancer drug-resistant cells. Exposure of cancer cells to BIM-46174 leads to caspase-3-dependent apoptosis and poly(ADP-ribose) polymerase cleavage. National Cancer Institute COMPARE analysis for BIM-46174 supports its novel pharmacologic profile compared with 12,000 anticancer agents. The growth rate of human tumor xenografts in athymic mice is significantly reduced after administration of BIM-46174 combined with either cisplatin, farnesyltransferase inhibitor, or topoisomerase inhibitors. Our data validate the feasibility of targeting heterotrimeric G-protein functions downstream the GPCRs to improve anticancer chemotherapy.

Original language	English
Pages (from-to)	9227-9234
Number of pages	8
Journal	Cancer Research
Volume	66
Issue number	18
DOIs	https://doi.org/10.1158/0008-5472.CAN-05-4205
Publication status	Published - Sept 15 2006
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/0008-5472.CAN-05-4205

Cite this

Prévost, G. P., Lonchampt, M. O., Holbeck, S., Attoub, S., Zaharevitz, D., Alley, M., Wright, J., Brezak, M. C., Coulomb, H., Savola, A., Huchet, M., Chaumeron, S., Nguyen, Q. D., Forgez, P., Bruyneel, E., Bracke, M., Ferrandis, E., Roubert, P., Demarquay, D., ... Kasprzyk, P. G. (2006). Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Gα/Gβγ protein complex. Cancer Research, 66(18), 9227-9234. https://doi.org/10.1158/0008-5472.CAN-05-4205

Prévost, GP, Lonchampt, MO, Holbeck, S, Attoub, S, Zaharevitz, D, Alley, M, Wright, J, Brezak, MC, Coulomb, H, Savola, A, Huchet, M, Chaumeron, S, Nguyen, QD, Forgez, P, Bruyneel, E, Bracke, M, Ferrandis, E, Roubert, P, Demarquay, D, Gespach, C & Kasprzyk, PG 2006, 'Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Gα/Gβγ protein complex', Cancer Research, vol. 66, no. 18, pp. 9227-9234. https://doi.org/10.1158/0008-5472.CAN-05-4205

@article{9efebf902f8442e3942c42c8fb3fdd3b,

title = "Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Gα/Gβγ protein complex",

abstract = "A large number of hormones and local agonists activating guanine-binding protein-coupled receptors (GPCR) play a major role in cancer progression. Here, we characterize the new imidazo-pyrazine derivative BIM-46174, which acts as a selective inhibitor of heterotrimeric G-protein complex. BIM-46174 prevents the heterotrimeric G-protein signaling linked to several GPCRs mediating (a) cyclic AMP generation (Gαs), (b) calcium release (Gαq), and (c) cancer cell invasion by Wnt-2 frizzled receptors and high-affinity neurotensin receptors (Gαo/i and Gαq). BIM-46174 inhibits the growth of a large panel of human cancer cell lines, including anticancer drug-resistant cells. Exposure of cancer cells to BIM-46174 leads to caspase-3-dependent apoptosis and poly(ADP-ribose) polymerase cleavage. National Cancer Institute COMPARE analysis for BIM-46174 supports its novel pharmacologic profile compared with 12,000 anticancer agents. The growth rate of human tumor xenografts in athymic mice is significantly reduced after administration of BIM-46174 combined with either cisplatin, farnesyltransferase inhibitor, or topoisomerase inhibitors. Our data validate the feasibility of targeting heterotrimeric G-protein functions downstream the GPCRs to improve anticancer chemotherapy.",

author = "Pr{\'e}vost, {Gr{\'e}goire P.} and Lonchampt, {Marie O.} and Susan Holbeck and Samir Attoub and Daniel Zaharevitz and Mike Alley and John Wright and Brezak, {Marie C.} and H{\'e}l{\`e}ne Coulomb and Ann Savola and Marion Huchet and Sophie Chaumeron and Nguyen, {Quang D{\'e}} and Patricia Forgez and Erik Bruyneel and Mark Bracke and Eric Ferrandis and Pierre Roubert and Dani{\'e}le Demarquay and Christian Gespach and Kasprzyk, {Philip G.}",

year = "2006",

month = sep,

day = "15",

doi = "10.1158/0008-5472.CAN-05-4205",

language = "English",

volume = "66",

pages = "9227--9234",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "18",

}

TY - JOUR

T1 - Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Gα/Gβγ protein complex

AU - Prévost, Grégoire P.

AU - Lonchampt, Marie O.

AU - Holbeck, Susan

AU - Attoub, Samir

AU - Zaharevitz, Daniel

AU - Alley, Mike

AU - Wright, John

AU - Brezak, Marie C.

AU - Coulomb, Hélène

AU - Savola, Ann

AU - Huchet, Marion

AU - Chaumeron, Sophie

AU - Nguyen, Quang Dé

AU - Forgez, Patricia

AU - Bruyneel, Erik

AU - Bracke, Mark

AU - Ferrandis, Eric

AU - Roubert, Pierre

AU - Demarquay, Daniéle

AU - Gespach, Christian

AU - Kasprzyk, Philip G.

PY - 2006/9/15

Y1 - 2006/9/15

N2 - A large number of hormones and local agonists activating guanine-binding protein-coupled receptors (GPCR) play a major role in cancer progression. Here, we characterize the new imidazo-pyrazine derivative BIM-46174, which acts as a selective inhibitor of heterotrimeric G-protein complex. BIM-46174 prevents the heterotrimeric G-protein signaling linked to several GPCRs mediating (a) cyclic AMP generation (Gαs), (b) calcium release (Gαq), and (c) cancer cell invasion by Wnt-2 frizzled receptors and high-affinity neurotensin receptors (Gαo/i and Gαq). BIM-46174 inhibits the growth of a large panel of human cancer cell lines, including anticancer drug-resistant cells. Exposure of cancer cells to BIM-46174 leads to caspase-3-dependent apoptosis and poly(ADP-ribose) polymerase cleavage. National Cancer Institute COMPARE analysis for BIM-46174 supports its novel pharmacologic profile compared with 12,000 anticancer agents. The growth rate of human tumor xenografts in athymic mice is significantly reduced after administration of BIM-46174 combined with either cisplatin, farnesyltransferase inhibitor, or topoisomerase inhibitors. Our data validate the feasibility of targeting heterotrimeric G-protein functions downstream the GPCRs to improve anticancer chemotherapy.

AB - A large number of hormones and local agonists activating guanine-binding protein-coupled receptors (GPCR) play a major role in cancer progression. Here, we characterize the new imidazo-pyrazine derivative BIM-46174, which acts as a selective inhibitor of heterotrimeric G-protein complex. BIM-46174 prevents the heterotrimeric G-protein signaling linked to several GPCRs mediating (a) cyclic AMP generation (Gαs), (b) calcium release (Gαq), and (c) cancer cell invasion by Wnt-2 frizzled receptors and high-affinity neurotensin receptors (Gαo/i and Gαq). BIM-46174 inhibits the growth of a large panel of human cancer cell lines, including anticancer drug-resistant cells. Exposure of cancer cells to BIM-46174 leads to caspase-3-dependent apoptosis and poly(ADP-ribose) polymerase cleavage. National Cancer Institute COMPARE analysis for BIM-46174 supports its novel pharmacologic profile compared with 12,000 anticancer agents. The growth rate of human tumor xenografts in athymic mice is significantly reduced after administration of BIM-46174 combined with either cisplatin, farnesyltransferase inhibitor, or topoisomerase inhibitors. Our data validate the feasibility of targeting heterotrimeric G-protein functions downstream the GPCRs to improve anticancer chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=33749473192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749473192&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-4205

DO - 10.1158/0008-5472.CAN-05-4205

M3 - Article

C2 - 16982767

AN - SCOPUS:33749473192

SN - 0008-5472

VL - 66

SP - 9227

EP - 9234

JO - Cancer Research

JF - Cancer Research

IS - 18

ER -

Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Gα/Gβγ protein complex

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this